Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.32
    +1.42 (+1.73%)
     

  • GOLD FUTURES

    2,336.30
    -10.10 (-0.43%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,174.64
    -344.07 (-0.64%)
     

  • CMC Crypto 200

    1,426.91
    +12.15 (+0.86%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

EU Commission clears Eli Lilly, Novartis deal

Reuters - UK Focus

(Adds details of deal)

BRUSSELS, Oct 3 (Reuters) - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis (Xetra: 904278 - news) 's animal health business on Friday.

The European Commission said it was satisfied that the deal would not hinder competition and cleared it unconditionally.

The bid will allow Lilly to strengthen and diversify its Elanco unit and is one of several announced in the healthcare sector in recent months as firms seek to gain scale or specialise in certain disease areas.

The Commission said the takeover would create overlaps between the activities of the two drugmakers in the markets for parasiticides and antimicrobials.

ADVERTISEMENT

But it concluded that more competitors could enter the market in the coming years and keep prices in check.

Novartis separately agreed in April to buy GlaxoSmithKline (Other OTC: GLAXF - news) 's oncology products for $14.5 billion and sell its vaccine business to the British drugmaker for $7.1 billion. (Reporting by Julia Fioretti; Editing by David Holmes)